NASDAQ:IPSC Century Therapeutics Q3 2024 Earnings Report $1.86 -0.02 (-1.06%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.86 -0.01 (-0.27%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Century Therapeutics EPS ResultsActual EPS-$0.37Consensus EPS -$0.45Beat/MissBeat by +$0.08One Year Ago EPS-$0.55Century Therapeutics Revenue ResultsActual Revenue$0.79 millionExpected Revenue$0.47 millionBeat/MissBeat by +$320.00 thousandYoY Revenue GrowthN/ACentury Therapeutics Announcement DetailsQuarterQ3 2024Date11/5/2024TimeAfter Market ClosesConference Call DateTuesday, November 5, 2024Conference Call Time9:00AM ETUpcoming EarningsCentury Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Century Therapeutics Earnings HeadlinesCentury Therapeutics (NASDAQ:IPSC) Raised to "Hold" at Wall Street ZenSeptember 12, 2026 | americanbankingnews.comCentury Therapeutics Appoints IECURE CEO Joseph Truitt To Board As CNTY-813 Nears IND FilingSeptember 10, 2026 | rttnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 19 at 1:00 AM | Stansberry Research (Ad)Century Therapeutics Appoints Joseph Truitt to Board of DirectorsSeptember 9, 2026 | globenewswire.comCentury Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesAugust 12, 2026 | finanznachrichten.deCentury Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesAugust 12, 2026 | globenewswire.comSee More Century Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email. Email Address About Century TherapeuticsCentury Therapeutics (NASDAQ:IPSC) is a biotechnology company focused on developing allogeneic cell therapies for cancer and other serious diseases. The company uses induced pluripotent stem cell (iPSC) technology, gene editing and cell-engineering methods to create potentially off-the-shelf immune cell therapies designed to recognize and eliminate diseased cells. Its pipeline has included engineered natural killer (NK) cell and T-cell programs targeting blood cancers. Among its leading programs is CNTY-101, an allogeneic CAR NK cell therapy directed at CD19, a target associated with certain B-cell malignancies. Century has also developed additional programs intended to address limitations of existing cell therapies, including challenges related to manufacturing, availability and treatment durability. Century Therapeutics was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. The company’s research and development activities are primarily focused on advancing cell therapy candidates through clinical development for patients in the United States and, where applicable, other regulated markets. Its therapies are investigational and have not been established as safe or effective for general commercial use.View Century Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
